Scopus BioPharma Inc. (SCPS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 7.45 Million USD | 78.75% |
| 2021 | 4.17 Million USD | 9.59% |
| 2020 | 3.8 Million USD | 345.3% |
| 2019 | 854.54 Thousand USD | 519.39% |
| 2018 | 137.96 Thousand USD | 23.98% |
| 2017 | 111.28 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 11 Million USD | 18.13% |
| 2023 Q1 | 9.31 Million USD | 24.94% |
| 2022 Q2 | 5.37 Million USD | 4.53% |
| 2022 FY | 7.45 Million USD | 78.75% |
| 2022 Q3 | 5.91 Million USD | 10.21% |
| 2022 Q4 | 7.45 Million USD | 25.93% |
| 2022 Q1 | 5.13 Million USD | 23.21% |
| 2021 Q3 | 2.23 Million USD | -74.55% |
| 2021 FY | 4.17 Million USD | 9.59% |
| 2021 Q2 | 8.79 Million USD | 96.29% |
| 2021 Q1 | 4.47 Million USD | 17.71% |
| 2021 Q4 | 4.17 Million USD | 86.4% |
| 2020 FY | 3.8 Million USD | 345.3% |
| 2020 Q4 | 3.8 Million USD | 0.44% |
| 2020 Q3 | 3.78 Million USD | 0.0% |
| 2019 Q4 | 854.54 Thousand USD | 0.0% |
| 2019 FY | 854.54 Thousand USD | 519.39% |
| 2019 Q1 | 363.64 Thousand USD | 0.0% |
| 2019 Q2 | 378.98 Thousand USD | 4.22% |
| 2018 FY | 137.96 Thousand USD | 23.98% |
| 2017 FY | 111.28 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -54.497% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -213.739% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 80.85% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 94.38% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -168.242% |
| Better Therapeutics, Inc. | 23.84 Million USD | 68.734% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 10.014% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 25.263% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 71.698% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 76.546% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 89.264% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 6.181% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 84.506% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 95.262% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -112.622% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 64.986% |
| Molecular Templates, Inc. | 31.17 Million USD | 76.085% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 40.436% |
| NexImmune, Inc. | 5.08 Million USD | -46.619% |
| Orgenesis Inc. | 35.53 Million USD | 79.022% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 54.854% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -2698.064% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -224.765% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 98.493% |
| Statera Biopharma, Inc. | 22.67 Million USD | 67.127% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 31.698% |
| Trevena, Inc. | 48.26 Million USD | 84.554% |
| Vaxxinity, Inc. | 30.94 Million USD | 75.91% |
| Vaccinex, Inc. | 5.94 Million USD | -25.453% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -278.717% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 80.574% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -169.936% |